[Form 4] Harvard Bioscience Inc Insider Trading Activity

Rhea-AI Filing Summary

Harvard Bioscience (HBIO) – Form 4 filing

Director Seth B. Benson reported the grant of 110,000 restricted stock units (RSUs) on 16-Jul-2025. The RSUs were awarded at a price of $0.00 and will fully vest on the earlier of the company’s next Annual Meeting after 16-Jul-2025 or on 16-Jul-2026.

Following the grant, Benson beneficially owns 110,000 common shares, held directly. No derivative securities, option exercises or share sales were disclosed. The transaction reflects routine director equity compensation and does not signal any change to Harvard Bioscience’s operating outlook or capital structure beyond a modest increase in outstanding shares.

Positive

• Equity award aligns director’s financial interests with shareholders

Negative

• Issuance of 110,000 new shares creates slight dilution to existing holders

Insights

Securities Analyst

TL;DR: 110k RSU grant aligns director incentives; immaterial dilution; overall neutral.

The Form 4 records a single transaction: Seth Benson, an HBIO director, received 110,000 RSUs that vest within one year. Because the award carries no exercise cost and represents standard board compensation, it bolsters management-shareholder alignment but is too small to materially affect share count or valuation. Absence of sales or derivative activity signals no bearish sentiment. Overall, the filing is procedurally important yet financially neutral for investors.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Benson Seth Benjamin

(Last) (First) (Middle)

C/O HARVARD BIOSCIENCE, INC.

84 OCTOBER HILL ROAD

(Street)

HOLLISTON MA 01746

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
HARVARD BIOSCIENCE INC [ HBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/16/2025		A		110,000(1)	A	$0.00	110,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of 110,000 restricted stock units that fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after July 16, 2025, immediately prior to the commencement of such meeting, and (ii) July 16, 2026.

	/s/ Seth Benson	07/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did HBIO director Seth Benson report in the latest Form 4?

He received 110,000 restricted stock units on 16-Jul-2025 at no cost.

How many HBIO shares does Seth Benson now own?

The director beneficially owns 110,000 common shares, held directly.

When will the newly granted HBIO RSUs vest?

They fully vest at the earlier of the next HBIO Annual Meeting after 16-Jul-2025 or on 16-Jul-2026.

Was there any cash paid for the RSUs?

No. The RSUs were granted at a $0.00 purchase price.

Did the filing disclose any stock sales by the director?

No sales or derivative exercises were reported; only the RSU grant was disclosed.